Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $30.52 and last traded at $30.17, with a volume of 217711 shares changing hands. The stock had previously closed at $29.79.
Gemini Therapeutics Trading Up 1.3 %
The firm’s 50-day simple moving average is $47.69 and its 200 day simple moving average is $53.84. The stock has a market cap of $1.31 billion, a P/E ratio of -13.50 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
- Five stocks we like better than Gemini Therapeutics
- The Significance of Brokerage Rankings in Stock Selection
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- Stock Splits, Do They Really Impact Investors?
- 3 Value Stocks You Can Buy Before They Become Big
- The Role Economic Reports Play in a Successful Investment Strategy
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
